Education
About Us
Working with TipRanks
Follow Us
ESSA Pharma Inc (EPIX)
NASDAQ:EPIX
EPIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.23 - $7.88
Previous Close$1.91
Volume3.03M
Average Volume (3M)10.03M
Market Cap
$12.45M
Enterprise Value-$34.16M
Total Cash (Recent Filing)$109.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Dec 23, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 25, 2025Dividend Yield718.85%
Share Statistics
EPS (TTM)-0.09
Shares Outstanding47,308,395
10 Day Avg. Volume29,264,811
30 Day Avg. Volume10,030,851
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-2.74
Enterprise Value/Revenue-251.63
Enterprise Value/Gross Profit-8.45K
Enterprise Value/Ebitda1.31
Forecast
1Y Price Target
$2.25Price Target Upside837.50% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityEPIX's last reported cash balance of $126.8M offers flexibility to evaluate opportunities.
Strategic OpportunitiesThe company will move to a strategic process in which it will explore options that maximize shareholder value.
Bears Say
Clinical TrialsEPIX announced the discontinuation of masofaniten's randomized Phase II trial in combination with enzalutamide in anti-androgen naive mCPRC following an interim analysis that suggested the trial was unlikely to meet the primary endpoint.
Drug DevelopmentEPIX announced that it will discontinue all masofaniten development following a pre-specified futility analysis that showed that this candidate failed to meet the target efficacy profile in the Phase 2 enzalutamide combo study in mCRPC patients naïve to second-generation antiandrogens.
ESSA Pharma News
EPIX FAQ
What was ESSA Pharma Inc’s price range in the past 12 months?
ESSA Pharma Inc lowest stock price was $0.23 and its highest was $7.88 in the past 12 months.
What is ESSA Pharma Inc’s market cap?
ESSA Pharma Inc’s market cap is $12.45M.
When is ESSA Pharma Inc’s upcoming earnings report date?
ESSA Pharma Inc’s upcoming earnings report date is Dec 23, 2025 which is in 115 days.
How were ESSA Pharma Inc’s earnings last quarter?
ESSA Pharma Inc released its earnings results on Aug 13, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.08.
Is ESSA Pharma Inc overvalued?
According to Wall Street analysts ESSA Pharma Inc’s price is currently Undervalued.
Does ESSA Pharma Inc pay dividends?
ESSA Pharma Inc pays a Notavailable dividend of $1.691 which represents an annual dividend yield of 718.85%. See more information on ESSA Pharma Inc dividends here
What is ESSA Pharma Inc’s EPS estimate?
ESSA Pharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ESSA Pharma Inc have?
ESSA Pharma Inc has 47,308,395 shares outstanding.
What happened to ESSA Pharma Inc’s price movement after its last earnings report?
ESSA Pharma Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ESSA Pharma Inc?
Currently, no hedge funds are holding shares in EPIX
ESSA Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.25 (837.50% Upside)
$2.25 (837.50% Upside)
Blogger Sentiment
Bullish
EPIX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 41.3%
Last 30 Days ▲ 40.5%
Last 30 Days ▲ 40.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-63.84%
12-Months-Change
Fundamentals
Return on Equity
-21.25%
Trailing 12-Months
Asset Growth
-16.71%
Trailing 12-Months
Company Description
ESSA Pharma Inc
ESSA Pharma Inc. (EPIX) is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. The company operates within the biotechnology and pharmaceutical sectors, with its core products centering around small molecule drugs that target the androgen receptor pathway in prostate cancer cells. ESSA Pharma's lead product candidate is EPI-7386, a next-generation androgen receptor inhibitor designed to provide therapeutic benefits for patients with metastatic castration-resistant prostate cancer (mCRPC).
Technical Analysis
Adverum Biotechnologies
―
I-MAB
―
Adagene
―
Unicycive Therapeutics
―
TScan Therapeutics
―
Ownership Overview
1.20% Insiders
0.05% Mutual Funds
52.10% Other Institutional Investors
46.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---